Close Menu

People in the News

Mar 10, 2021

Ontera: Paul Marr, John Sperzel

Nanopore sensing and diagnostics company Ontera has appointed Paul Marr as its chief commercial officer and John Sperzel to its board of directors.

Marr has more than 22 years of in vitro diagnostics sales leadership experience that will be critical to the commercialization strategy for Ontera's NanoDetector device, the firm said. Prior to Ontera, he led the US laboratory sales team in providing high-throughput molecular diagnostic testing solutions at Hologic. Previously, he held various sales leadership roles at Beckman Coulter, Leica Biosystems, Siemens, and Ventana Medical Systems.

Sperzel, the president and CEO of T2 Biosystems, was previously president and CEO of Chembio Diagnostics. He was also president and CEO of ITC Medical and held executive leadership positions at Axis-Shield, Bayer Diagnostics, Instrumentation Laboratory, and Boehringer Mannheim.

Mar 10, 2021

GRIP Molecular: Edward Ludwig, Bruce Batten, Edward Gillen

GRIP Molecular has formed a board of directors with Edward Ludwig as its chairman. The board also comprises the company's Founder, President, and CSO Bruce Batten, and its CEO Edward Gillen. Ludwig is a former President and CEO of Becton Dickinson and currently serves on the boards of CVS Health and Boston Scientific. He is also a former board member of AdvaMed and a past chair of the health advisory board for the Johns Hopkins Bloomberg School of Public Health.

Batten previously was the founder and/or CEO of four technology starters and held executive positions at companies including Thermo Instruments, CyberOptica, and Advantek. Gillen was previously at BD where he held several positions including worldwide senior director, strategy and business development, Diabetes Care Division; global VP and GM, Surgical and Anesthesia Systems, Advanced Drug Delivery; and global business leader, Vaccine Delivery. 

Based in Minnesota, GRIP is developing an electronic biosensor for the detection of multiple biomarkers in a single test. The firm was founded in late 2019 and has licensed technology from the University of Minnesota, according to its website. Its first product will be targeted at upper respiratory infection with a planned launch in 2023.

Mar 09, 2021

Agilent: Katharine Knobil

Agilent has appointed Katharine Knobil as the firm's first chief medical officer. Prior to Agilent, Knobil served as CMO and head of research and development at Kaleido Biosciences. Knobil has also served in a variety of leadership positions at GlaxoSmithKline. She currently serves on the board of directors of Arena Pharmaceuticals. 

Mar 08, 2021

Chembio Diagnostics: David Bespalko

Chembio Diagnostics has appointed David Bespalko to its board of directors. Bespalko brings more than 35 years of leadership experience in the global in vitro diagnostics market, the firm said. Most recently he was group vice president at Thermo Fisher Scientific's Global Commercial Operations Specialty Diagnostics Group. He joined Thermo Fisher in 2011 as president of Fisher Healthcare. At Thermo Fisher, Bespalko held additional roles including president of the firm's Global Anatomical Pathology Division. Previously, he was corporate vice president North America for commercial operations at Beckman Coulter. His diagnostics career began in Canada with commercial and general management roles at Baxter Healthcare and Dade Behring. Bespalko now manages his own consulting firm, BMC, which advises early-stage companies and provides executive mentorship.

Mar 05, 2021

Quidel: Joseph Wilkins

Quidel has expanded the size of its board of directors from nine to ten members and appointed Joseph Wilkins to the board.

Wilkins is a partner at healthcare consulting firm TRG Healthcare, a limited partner at privately-held venture capital fund Tech Council Ventures, and is an advisor with Touchdown Ventures, a privately held venture capital group. He previously served as senior vice president and chief transformation and innovation officer for Atlantic Health System, an integrated healthcare delivery system, and prior to that he held positions at Quest Diagnostics and Danaher subsidiary Beckman Coulter.

Mar 05, 2021

Prometheus Biosciences: Mark Stenhouse

Prometheus Biosciences, a developer of therapeutic and companion diagnostic products for inflammatory bowel disease, has appointed Mark Stenhouse as chief operating officer. Stenhouse previously served as general manager of the screening business at Exact Sciences. He previously spent nearly 30 years at Abbott Laboratories/AbbVie, most recently as vice president of US immunology. He was also vice president and general manager of the gastroenterology franchise, having spent 10 years working in IBD. Stenhouse currently is a member of the board of directors for Phathom Pharmaceuticals.

Mar 04, 2021

Precipio: Ron Andrews

Precipio has announced that Ron Andrews has joined the company's board of directors. In addition to currently serving as CEO of molecular diagnostics firm OncoCyte, Andrews' past experiences include a term as CEO of Roche Molecular, president of the genetic science division at Thermo Fisher Scientific, president of the medical sciences venture at Life Technologies, and CEO of Clarient.

Mar 03, 2021

Geneoscopy: Vince Wong

Geneoscopy has appointed Vince Wong as it chief commercial officer. Wong previously served as VP of sales at Roche Diagnostics. He has also served as VP and general manager of physician office and specialty diagnostics at the firm. 

Mar 03, 2021

Transplant Genomics: Nicholas Grund, John Slaught, Charles Argentine

Transplant Genomics has appointed Nicholas Grund as president, John Slaught as vice president of sales, and Charles Argentine as director of clinical operations.

Grund will be responsible for developing and implementing new strategies to grow Transplant Genomics' existing business, expanding the company's TruGraf portfolio into new organ types, and working with customers, advocates, and payors to establish long-term relationships. He will head company initiatives to increase TruGraf usage in the community-based nephrology market, and will also shepherd the launch of TruGraf Liver in the second half of 2021.

Grund has more than 25 years of commercial leadership experience in the biopharmaceutical industry, including several global executive roles in finance, sales, and marketing. He previously served as chief commercial officer at AMAG Pharmaceuticals, and also spent 13 years at Sanofi, most recently as the leader of the company's rare disease and multiple sclerosis franchises in the Asia Pacific region and Canada. 

Slaught has more than 25 years of commercial team leadership. He most recently served as VP of sales for Optum.

Argentine has more than 15 years of laboratory management experience, primarily in the areas of genetic sequencing and immunology. He most recently served as director of clinical laboratory operations at Roche Sequencing Solutions.

Feb 25, 2021

Quest Diagnostics: Timothy Ring, Daniel Stanzione, Vicky Gregg

Quest Diagnostics announced Timothy Ring will replace Daniel Stanzione as the company's lead independent director, following the annual meeting and subject to Ring's reelection to the board. Stanzion is stepping down from the board, on which he has served since 1997. He became Quest's first lead independent director on 2003. Ring is the former chairman and CEO of CR Bard. Also, Vicky Gregg will take over as chair of the compensation committee, replacing Ring, subject to her reelection. Gregg is the former CEO of Blue Cross Blue Shield of Tennessee.

Feb 23, 2021

Ortho Clinical Diagnostics: Evelyn Dilsaver

Ortho Clinical Diagnostics has appointed Evelyn Dilsaver as a member of its board of directors and chair of its audit committee. From 2004 to 2007, Dilsaver served as the president and CEO of Charles Schwab Investment Management, the mutual fund arm of Charles Schwab, and helped grow the business from $132 billion to more than $200 billion in assets. She also served in leadership roles at Schwab for more than 16 years, including controller and chief of staff to the co-CEO. Dilsaver began her career at Ernst & Young, where she specialized in the banking and savings and loan industries.

Feb 23, 2021

Co-Diagnostics: Brian Brown, Jesse Montgomery, Reed Benson, Brent Satterfield

Co-Diagnostics has appointed Brian Brown as its CFO and Jesse Montgomery as its chief scientific officer (CSO). Co-Diagnostics' former CFO Reed Benson will remain with the company as its general counsel. Further, Brent Satterfield, the firm's founder and former CSO, will continue to be involved as the head of its scientific advisory board. Brown previously held the roles of CFO, vice president of accounting and investor relations, and director of finance for public and private companies.

Feb 23, 2021

Quotient Limited: Manuel Mendez

Quotient Limited has appointed Manuel Mendez its CEO, replacing Franz Walt, who is retiring after serving as CEO since 2018. Mendez has more than 30 years of experience in the diagnostics and life science spaces and was previously at Quest Diagnostics where he was SVP and chief commercial officer. Before that, he was SVP and head of global commercial operations at Qiagen where he was also a member of its executive committee. He has also held senior leadership positions at Abbott Laboratories, Thermo Fisher Scientific, OraSure Technologies, and BioMérieux.

Feb 23, 2021

Qiagen: Thomas Ebeling

Thoms Ebeling has been appointed to Qiagen's supervisory board. Ebeling has been an advisor in recent years to various companies after having served as CEO of German media group ProSiebenSat.1 from 2009 to 2018. Prior to that he worked for Novartis from 1997 to 2008, including as CEO of Novartis Pharmaceuticals and CEO of Novartis Consumer Health. Ebeling has also previously served on the supervisory boards of Bayer and Lonza.

Feb 22, 2021

Aspira Women's Health: Nicole Sandford

Aspira Women's Health has appointed Nicole Sandford to its board of directors. She was previously the executive vice president and global board services leader at Ellig Group, and prior to that Sandford was at Deloitte from 1993 to 2020, most recently as the national managing partner for its regulatory and operational risk practice.

Feb 19, 2021

Siemens Healthineers, Centogene: Peer Schatz

Peer Schatz was elected to the supervisory board of Siemens Healthineers on Feb. 12 at the company's annual shareholders' meeting. The company proposed his addition to the board on Jan. 5.

In addition, Schatz has become chairman of the supervisory board of Centogene, effective Jan. 1, 2021, after having joined the board last summer. He replaced Flemming Ornskov, who was chairman from April 1, 2019 until Dec. 31, 2020.

Schatz is the former CEO of Qiagen, a position he held from 1993 until 2019. He is currently managing director of PS Capital Management and is chairman of the board and cofounder of spatial genomics startup Resolve Biosciences. Before Qiagen, he had various roles at ComputerLand and at Sandoz and cofounded several startup companies in the IT industry. Schatz holds an master's degree in finance from the University of St. Gallen and an MBA from the University of Chicago Graduate School of Business.

Feb 19, 2021

Myriad Genetics: Kevin Haas, Faith Zaslavsky

Myriad Genetics has promoted Kevin Haas and Faith Zaslavsky. Haas, will be Myriad's new chief technology officer and report to CEO Paul Diaz. He has held various senior level positions in R&D, bioinformatics, engineering, and technology since joining the company in 2013. Zaslavsky will be president of the Myriad Oncology business unit, which she has been general manager of since 2019.

Feb 18, 2021

Infinity BiologiX: Shareef Nahas, Sameer Kalghatgi

Infinify BiologiX (IBX) has named Shareef Nahas as vice president of global laboratory operations and clinical services and interim CSO, and Sameer Kalghatgi as senior director of laboratory operations.

Nahas will report to Robin Grimwood, president and interim CEO of IBX. Nahas and Grimwood assume their interim roles following the recent passing of Andrew Brooks. Nahas was previously senior director of operations at Rady Children's Institute of Genomic Medicine in San Diego. Prior to that he held a number of senior laboratory roles at Genoptix (Novartis) and Ambry Genetics. He received his PhD in molecular toxicology from the University of California, Los Angeles.

Kalghatgi joins IBX from Coriell Institute for Medical Research, where he served as director of laboratory operations. He will report to Nahas at IBX.

IBX previously operated as RUCDR Infinite Biologics before spinning off from Rutgers University-New Brunswick in August 2020. Its COVID-19 saliva test was the first to receive US Food and Drug Administration Emergency Use Authorization. The company primarily provides sample collection, processing, storage, and analytical services to research and clinical customers.

Feb 18, 2021

Delfi Diagnostics: Tara Maddala, Allison Ryan

Delfi Diagnostics has appointed Tara Maddala as its VP of clinical development and Allison Ryan as VP of data science. Maddala previously served as VP of biostatistics and data managment at Grail. Ryan previously served as VP of data science at Natera. 

Feb 16, 2021

NephroSant: Mark Capone

Mark Capone has joined the board of directors of NephroSant, a spinout from the University of California, San Francisco that is developing noninvasive testing solutions for kidney health. He is the president and CEO of Precision Medicine Advisors. Before that, he was president and CEO of Myriad Genetics, and prior to that, he held various positions at Eli Lilly. Capone holds a BS in chemical engineering from Penn State University and an MS in chemical engineering and in management from the Massachusetts Institute of Technology.

Feb 16, 2021

1health: Mostafa Ronaghi

Testing-as-a-service company 1health has appointed Mostafa Ronaghi to its board of directors. Ronaghi was chief technology and senior vice president at Illumina for about 13 years. He also cofounded the Illumina Accelerator and spinoff company Grail. Ronaghi also cofounded several other genomics and life science data ventures, including Avantome, ParAllele Bioscience, NextBio, and Pyrosequencing. Prior to these ventures, he was a principal investigator at Stanford University from 1999 to 2008, focusing on the development of molecular diagnostic applications.

Feb 12, 2021

LexaGene: Daryl Rebeck, Stephen Mastrocola

LexaGene said this week that Daryl Rebeck will resign from the company's board and his position as president effective Feb. 15. The company also said that Stephen Mastrocola has joined the board of directors. Mastrocola recently retired from Ernst & Young after 19 years, where he was a senior assurance partner and led the firm's New England Assurance Practice for several years. Prior to this, he was an assurance partner at Arthur Andersen.

Feb 10, 2021

Sema4: Nat Turner, Emily Leproust, Eli Casdin

Sema4 has appointed three new members to its board of directors, who will take up their posts after the firm has gone public through a planned merger with special purpose acquisition company CM Life Sciences.

The new members are Nat Turner, cofounder and CEO of Flatiron Health; Emily Leproust, cofounder and CEO of Twist Bioscience; and Eli Casdin, founder and chief investment officer of Casdin Capital.

Feb 09, 2021

LabCorp: Prasanth Reddy, Robert Phillips

Laboratory Corporation of America has appointed Prasanth Reddy its SVP and enterprise oncology head of the firm's enterprise oncology unit, and Robert Phillips its VP and head of enterprise oncology science. The enterprise oncology unit will leverage LabCorp's drug development and diagnostics businesses to personalize cancer treatments for patients, the Burlington, North Carolina-based company said. Reddy was most recently VP of medical affairs at Foundation Medicine. Before that, he developed oncology service line treatment pathways at the Adventist Health System. Phillips joins LabCorp from Daiichi-Sankyo where he was VP and head of translational science and oversaw that firm's companion diagnostics efforts. He also was VP and head of precision medicine at Pfizer and was head of precision medicine at Regeneron Pharmaceuticals where he also founded the Regeneron Genetics Center.

Feb 08, 2021

DermTech: Lisa Beck, George Han

DermTech has appointed Lisa Beck and George Han to its scientific advisory board.

Beck is co-director of the University of Rochester Medical Center for Allergic Disease and has served on the board of the directors of the International Eczema Council since 2014. She also serves as president-elect of the Society of Investigative Dermatology. 

Han currently serves as the systems medical director for dermatology and chief of teledermatology at Mount Sinai Health System. He is also the current VP of the Dermatologic Society of Greater New York and a member of the Medical Board of the National Psoriasis Foundation. 

Pages